CYTK
Cytokinetics, Incorporated
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-18/100
Last price
62.41
▼ 0.29 (0.46%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
62.70
Prev close
62.70
Day high
62.53
Day low
60.68
Volume
3.23M
Market cap
$8.53B
P/E (TTM)
—
52W range
54.30 – 88.31
Day trading desk
Gap from prior close
-0.00%
Prior close 62.70
VWAP
61.40
+1.65% from price
Relative volume
1.38×
Normal
Session range
10.15%
59.00 – 64.99
Position in range
57%
Mid range
ATR (14D)
2.16
3.47% of price
Prior day high
65.76
PDH
Prior day low
62.19
PDL
Bid / ask spread
—
Quote not published
Session volume
2.71M
Avg 1.96M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.54%
-8.5%
1M
-15.64%
-16.8%
3M
-27.72%
-32.2%
6M
-6.31%
-24.5%
YTD
-3.45%
-17.7%
1Y
+7.69%
-8.7%
3Y
+108.25%
+26.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CYTK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-62.33K
Net selling
Buy transactions
51
374.59K shares
Sell transactions
42
436.91K shares
Net transactions
+93
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
896.70K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 28, 26 | BLUM ROBERT I Chief Executive Officer |
CONVERSION | 7.50K | $79.50K | Direct |
| Sep 28, 26 | BLUM ROBERT I Chief Executive Officer |
SELL | 7.50K | $490.95K | Direct |
| Sep 22, 26 | MALIK FADY IBRAHAM Officer |
CONVERSION | 3.50K | $27.30K | Direct |
| Sep 22, 26 | MALIK FADY IBRAHAM Officer |
SELL | 3.50K | $239.01K | Direct |
| Sep 15, 26 | LANDRY ROBERT E Director |
SELL | 1.00K | $72.13K | Direct |
| Sep 15, 26 | BLUM ROBERT I Chief Executive Officer |
SELL | 105.43K | $7.34M | |
| Sep 14, 26 | BLUM ROBERT I Chief Executive Officer |
CONVERSION | 7.50K | $79.50K | Direct |
| Sep 14, 26 | BLUM ROBERT I Chief Executive Officer |
STOCK | 99.28K | $0 | Direct |
| Sep 11, 26 | LANDRY ROBERT E Director |
SELL | 1.00K | $74.66K | Direct |
| Sep 8, 26 | MALIK FADY IBRAHAM Officer |
CONVERSION | 3.50K | $27.30K | Direct |
| Sep 8, 26 | MALIK FADY IBRAHAM Officer |
SELL | 3.50K | $264.11K | Direct |
| Sep 1, 26 | PARSHALL B LYNNE Director |
SELL | 5.00K | $357.40K | Direct |
| Aug 31, 26 | BLUM ROBERT I Chief Executive Officer |
CONVERSION | 7.50K | $79.50K | Direct |
| Aug 31, 26 | CALLOS ANDREW Officer |
CONVERSION | 10.00K | $232.60K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BHANJI MUNA |
Director | 26.36K | Stock Award(Grant) |
BLUM ROBERT I |
Chief Executive Officer | 282.71K | Conversion of Exercise of derivative security |
CALLOS ANDREW |
Officer | 58.55K | Conversion of Exercise of derivative security |
HARRINGTON ROBERT ARTHUR |
Director | 21.93K | Stock Award(Grant) |
HENDERSON JOHN TANNAHILL |
Director | 78.44K | Stock Award(Grant) |
HESSEKIEL JEFFREY J |
Officer | 107.94K | Stock Award(Grant) |
LEE SUNG |
Chief Financial Officer | 63.22K | Conversion of Exercise of derivative security |
MALIK FADY IBRAHAM |
Officer | 153.90K | Conversion of Exercise of derivative security |
WIERENGA WENDELL |
Director | 35.56K | Stock Award(Grant) |
WYSENSKI NANCY J |
Director | 33.99K | Stock Award(Grant) |
Fundamentals
Market cap$8.53B
Enterprise value$8.79B
Revenue (TTM)$67.67M
Gross profit$-337.44M
EBITDA$-695.36M
Net income$-894.00M
EPS (TTM)$-7.07
Free cash flow$-397.41M
Total cash$1.17B
Total debt$1.42B
Book value / share$-1.25
Shares outstanding139.02M
Float138.49M
Short % of float19.20%
Dividend yield0.00%
Beta (5Y)0.41
Valuation & profitability ratios
Trailing P/E—
Forward P/E-13.78
PEG ratio—
Price / sales—
Price / book—
EV / revenue129.86
EV / EBITDA-12.64
Gross margin0.00%
Operating margin-625.95%
Profit margin0.00%
Return on equity—
Return on assets-28.09%
Debt / equity—
Current ratio6.66
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $88.04M | $18.47M | $7.53M | $94.59M | +376.6% |
| Operating revenue | $88.04M | $18.47M | $7.53M | $94.59M | +376.6% |
| Cost of revenue | $416.03M | $339.41M | $330.12M | $240.81M | +22.6% |
| Gross profit | -$327.99M | -$320.93M | -$322.59M | -$146.22M | -2.2% |
| Research & development | $416.03M | $339.41M | $330.12M | $240.81M | +22.6% |
| Selling, general & admin | $284.27M | $215.31M | $173.61M | $177.98M | +32.0% |
| Total operating expense | $700.30M | $554.72M | $503.74M | $418.79M | +26.2% |
| Operating income | -$612.26M | -$536.25M | -$496.20M | -$324.20M | -14.2% |
| Net interest income | -$55.45M | -$34.98M | -$30.04M | -$39.81M | -58.5% |
| Pre-tax income | -$784.96M | -$589.53M | -$526.24M | -$388.95M | -33.2% |
| Net income | -$784.96M | -$589.53M | -$526.24M | -$388.95M | -33.2% |
| Net income to common | -$784.96M | -$589.53M | -$526.24M | -$388.95M | -33.2% |
| Basic EPS | -6.54 | -5.26 | -5.45 | -4.33 | -24.3% |
| Diluted EPS | -6.54 | -5.26 | -5.45 | -4.33 | -24.3% |
| EBIT | -$681.09M | -$503.01M | -$468.58M | -$337.80M | -35.4% |
| EBITDA | -$670.96M | -$493.48M | -$456.68M | -$331.99M | -36.0% |
| Basic shares | 120.10M | 111.98M | 96.52M | 89.83M | +7.3% |
| Diluted shares | 120.10M | 111.98M | 96.52M | 89.83M | +7.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $122.52M | $94.86M | $113.02M | $65.58M | +29.2% |
| Cash & short-term investments | $882.22M | $1.08B | $614.82M | $782.58M | -18.0% |
| Accounts receivable | $17.76M | $16.65M | $1.28M | $147.00K | +6.7% |
| Total current assets | $916.98M | $1.11B | $628.05M | $795.19M | -17.2% |
| Property, plant & equipment | $155.17M | $140.97M | $147.74M | $163.19M | +10.1% |
| Total assets | $1.42B | $1.40B | $824.32M | $1.01B | +1.6% |
| Total current liabilities | $202.45M | $179.67M | $102.68M | $84.62M | +12.7% |
| Current debt | $41.18M | $11.52M | $10.08M | $958.00K | +257.5% |
| Long-term debt | $1.12B | $645.60M | $607.37M | $609.62M | +72.9% |
| Total debt | $1.28B | $788.68M | $755.77M | $750.30M | +62.8% |
| Total liabilities | $2.08B | $1.54B | $1.21B | $1.12B | +35.6% |
| Retained earnings | -$3.49B | -$2.70B | -$2.11B | -$1.59B | -29.1% |
| Shareholder equity | -$659.63M | -$135.37M | -$386.32M | -$107.90M | -387.3% |
| Working capital | $714.52M | $928.27M | $525.37M | $710.57M | -23.0% |
| Net tangible assets | -$659.63M | -$135.37M | -$386.32M | -$107.90M | -387.3% |
| Shares issued | 122.94M | 118.21M | 101.64M | 94.83M | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$784.96M | -$589.53M | -$526.24M | -$388.95M | -33.2% |
| Depreciation & amortisation | $10.13M | $9.53M | $11.89M | $5.81M | +6.2% |
| Stock-based compensation | $112.29M | $97.84M | $72.06M | $47.85M | +14.8% |
| Change in working capital | -$35.63M | $35.66M | $3.09M | -$24.70M | -199.9% |
| Operating cash flow | -$510.01M | -$395.89M | -$414.33M | -$299.52M | -28.8% |
| Capital expenditure | -$24.81M | -$3.91M | -$1.42M | -$11.34M | -535.1% |
| Investing cash flow | $16.67M | -$553.10M | $239.25M | -$262.13M | +103.0% |
| Financing cash flow | $524.46M | $930.61M | $221.32M | $516.17M | -43.6% |
| Free cash flow | -$534.82M | -$399.80M | -$415.75M | -$310.85M | -33.8% |
| End cash position | $125.63M | $95.23M | $113.40M | $67.18M | +31.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $28.62M | $19.36M | $17.75M | $1.94M | $66.77M | +47.9% |
| Operating revenue | $28.62M | $19.36M | $17.75M | $1.94M | $66.77M | +47.9% |
| Cost of revenue | $5.59M | $2.55M | $104.40M | $99.23M | $2.42M | +119.1% |
| Gross profit | $23.03M | $16.80M | -$86.64M | -$97.30M | $64.35M | +37.1% |
| Research & development | $97.81M | $95.53M | $104.40M | $99.23M | $110.14M | +2.4% |
| Selling, general & admin | $104.40M | $104.90M | $91.72M | $69.46M | $65.72M | -0.5% |
| Total operating expense | $202.20M | $200.42M | $196.12M | $168.69M | $175.86M | +0.9% |
| Operating income | -$179.17M | -$183.62M | -$178.37M | -$166.75M | -$111.51M | +2.4% |
| Net interest income | -$20.89M | -$22.31M | -$18.86M | -$16.07M | -$11.26M | +6.4% |
| Pre-tax income | -$198.76M | -$206.03M | -$183.03M | -$306.18M | -$134.37M | +3.5% |
| Net income | -$198.76M | -$206.03M | -$183.03M | -$306.18M | -$134.37M | +3.5% |
| Net income to common | -$198.76M | -$206.03M | -$183.03M | -$306.18M | -$134.37M | +3.5% |
| Basic EPS | -1.50 | -1.67 | -1.50 | -2.55 | -1.12 | +10.2% |
| Diluted EPS | -1.50 | -1.67 | -1.50 | -2.55 | -1.12 | +10.2% |
| EBIT | -$163.93M | -$172.70M | -$152.70M | -$279.86M | -$110.11M | +5.1% |
| EBITDA | -$160.30M | -$169.32M | -$149.84M | -$277.18M | -$107.82M | +5.3% |
| Basic shares | 132.09M | 123.27M | 122.43M | 119.98M | 119.46M | +7.1% |
| Diluted shares | 132.09M | 123.27M | 122.43M | 119.98M | 119.46M | +7.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $255.27M | $129.84M | $122.52M | $225.47M | $74.94M | +96.6% |
| Cash & short-term investments | $1.17B | $818.55M | $882.22M | $962.53M | $858.13M | +42.4% |
| Accounts receivable | $24.43M | $6.83M | $17.76M | $1.81M | $8.41M | +257.9% |
| Inventory | $380.00K | $154.00K | — | — | — | +146.8% |
| Total current assets | $1.21B | $839.47M | $916.98M | $977.35M | $886.54M | +44.0% |
| Property, plant & equipment | $151.81M | $156.98M | $155.17M | $153.58M | $146.34M | -3.3% |
| Total assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | +51.1% |
| Total current liabilities | $181.43M | $199.19M | $202.45M | $142.14M | $131.06M | -8.9% |
| Current debt | $27.36M | $44.81M | $41.18M | $17.28M | $14.40M | -38.9% |
| Long-term debt | $1.12B | $1.12B | $1.12B | $1.05B | $713.04M | +0.2% |
| Total debt | $1.27B | $1.29B | $1.28B | $1.20B | $858.06M | -1.4% |
| Total liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | -0.1% |
| Retained earnings | -$3.89B | -$3.69B | -$3.49B | -$3.30B | -$3.00B | -5.4% |
| Shareholder equity | -$173.49M | -$826.57M | -$659.63M | -$521.12M | -$368.72M | +79.0% |
| Working capital | $1.03B | $640.28M | $714.52M | $835.21M | $755.48M | +60.4% |
| Net tangible assets | -$173.49M | -$826.57M | -$659.63M | -$521.12M | -$368.72M | +79.0% |
| Shares issued | 138.76M | 124.24M | 122.94M | 122.12M | 119.60M | +11.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$198.76M | -$206.03M | -$183.03M | -$306.18M | -$134.37M | +3.5% |
| Depreciation & amortisation | $3.63M | $3.38M | $2.86M | $2.68M | $2.29M | +7.5% |
| Stock-based compensation | $35.71M | $30.39M | $30.51M | $30.70M | $27.54M | +17.5% |
| Change in working capital | -$25.24M | -$219.00K | -$1.84M | $22.53M | -$51.11M | -11,425.6% |
| Operating cash flow | -$159.84M | -$145.46M | -$142.65M | -$107.50M | -$128.24M | -9.9% |
| Capital expenditure | -$4.33M | -$5.93M | -$5.64M | -$9.35M | -$4.14M | +26.9% |
| Investing cash flow | -$507.00M | $145.49M | -$71.19M | -$70.98M | $52.88M | -448.5% |
| Financing cash flow | $792.86M | $7.77M | $110.70M | $330.47M | $78.53M | +10,104.1% |
| Free cash flow | -$164.17M | -$151.39M | -$148.29M | -$116.86M | -$132.38M | -8.4% |
| End cash position | $258.38M | $132.95M | $125.63M | $228.58M | $76.55M | +94.3% |
Options analytics
Put / call volume
0.06
Call-heavy session
Put / call open interest
0.62
Positioning, not flow
Max pain
70.00
+14.1% from spot
ATM implied vol
52.6%
Nearest strike to spot
Skew (10% OTM)
+2.5%
Puts bid over calls
Call volume
375
Contracts, this expiry
Put volume
22
Contracts, this expiry
Heaviest call OI
65.00
930 contracts
Heaviest put OI
60.00
819 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.60 | -1.50 | +6.3% |
| Mar 2026 | -1.65 | -1.67 | -1.3% |
| Dec 2025 | -1.37 | -1.50 | -9.7% |
| Sep 2025 | -1.57 | -1.54 | +1.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.43 | 16 | $39.88M | +1,960.0% |
| Next quarter | -1.41 | 16 | $58.33M | +228.5% |
| Current year | -5.94 | 16 | $149.77M | +70.1% |
| Next year | -4.45 | 16 | $424.81M | +183.6% |
Analyst targets & ownership
Mean target$109.90
High target$146.00
Low target$85.00
Implied upside76.09%
Analyst count20
ConsensusSTRONG BUY
Strong buy / Buy7 / 13
Hold2
Sell / Strong sell0 / 0
Held by insiders0.64%
Held by institutions125.94%
Institutions holding657
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
64.91
-3.85% from price
SMA 20
67.78
-9.49% from price
SMA 50
72.88
-15.82% from price
SMA 100
75.64
-17.49% from price
SMA 200
70.16
-12.56% from price
EMA 12
65.52
-4.74% from price
EMA 26
68.41
-8.77% from price
EMA 50
71.28
-12.44% from price
RSI (14)
24.5
Oversold
MACD (12,26,9)
-2.89
Hist -0.29
ATR (14)
2.16
3.53% of price
Realised vol 30D
35.6%
Annualised
Bollinger upper
74.82
20, 2σ
Bollinger lower
60.74
20, 2σ
50 / 200 cross
Golden
72.88 vs 70.16
Trend bias
Below 200
-12.56%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.80
Less volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
35.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.7%
Peak to trough
Max drawdown 5Y
-72.4%
Peak to trough
ATR 14
2.16
3.53% of price
Beta (reported)
0.41
5Y monthly, from filing
Short interest
Shares short
17.48M
Prior 16.32M
Change vs prior
+7.1%
Shorts adding
% of float
19.20%
Elevated
% of shares out
12.57%
Against total outstanding
Days to cover
9.9
Crowded exit
Float
138.49M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 13, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 10, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 7, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 29, 26 | UBS | UPGRADE | Neutral | Buy |
| Jun 24, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jun 17, 26 | Needham | MAINTAINED | Buy | Buy |
| May 19, 26 | Citigroup | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:6
Split dateJun 25, 2013
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-28
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-06
Offering Registrations
S-8 · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-08
Periodic Financial Reports
10-Q · 2026-05-05
Annual Report to Shareholders
ARS · 2026-04-17
Periodic Financial Reports
10-K · 2026-02-26
Headlines
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Zacks · 5d ago
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
GlobeNewswire · 5d ago
Cytokinetics Starts Real-World Study of Myqorzo in Obstructive Hypertrophic Cardiomyopathy
MT Newswires · 7d ago
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire · 7d ago
Cytokinetics Insider Sold Shares Worth $490,950, According to a Recent SEC Filing
MT Newswires · 8d ago
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
MarketBeat · 12d ago
Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?
Insider Monkey · 14d ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.